Advertisement Covers CROI 2017


Tenofovir Alafenamide Exposure Is Modestly Higher in Children Than Adults

April 2017

Tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) exposures are slightly higher in children aged 6-12 years compared with adults, according to data presented at CROI 2017.

The original tenofovir formulation, tenofovir disoproxil fumarate (TDF) is not a recommended first-line nucleos(t)ide reverse transcriptase inhibitor in children. This is due to its association with bone and renal toxicity -- linked to plasma exposure. TAF provides 91% lower TFV exposure than TDF and is considered to have better renal and bone safety in adults and adolescents. There is interest in the potential benefits of TAF for paediatric HIV.

TAF is currently commercially available for adults and adolescents from the originator manufacturer (Gilead Sciences) within fixed dose combinations (FDC) and co-formulations, which are under investigation for children.

The company showed 24 week findings from a pharmacokinetic (PK), safety and efficacy study of the once daily FDC elvitegravir/cobicistat/emtricitabine/TAF (E/C/F/TAF) 150/150/200/10 mg, which is approved for adults and adolescents aged 12 and above.

The study was a phase 2/3, single-arm, open-label, 48 week, switch trial. Eligible children were aged 6-12 years, weighing at least 25 kg and virologically suppressed (<50 copies/mL) on stable antiretroviral therapy (ART) for six months or more.

PK assessments were made on all the agents in the FDC, as well as TFV, at steady state. These were compared with adult values. Adverse events (AE), laboratory tests, including viral load, were also conducted. Bone mineral density (BMD) z-score was assessed every 24 weeks

The study enrolled 23 children: median age 10 years (range 8 to 11), median weight 31 kg (range 26 to 58), 14 (61%) female, 18 (78%) black, median CD4 count 969 cells/mm3 (range 603 to 1421).

At 24 weeks mean AUCtau were 333 h*ng/mL (45% coefficient of variation) and 440 (21% coefficient of variation) for TAF and TFV respectively. These were modestly higher than adult values, but within safe and efficacious ranges of adults. Exposures of the other agents in the FDC followed a similar pattern.

No child had a serious AE or one leading to study drug discontinuation. No child had proximal renal tubulopathy. Median per cent change in BMD at 24 weeks was +4.2% for spine and +1.2% for total body less head Median change in BMD height-adjusted z-score was +0.10 for spine and -0.12 for TBLH.


Gaur A et al. Pharmacokinetics, safety & efficacy of E/C/F/TAF in HIV-infected children (6-12 yrs). CROI 2017. 13-17 February 2017. Poster abs 424. (Abstract and poster)

Related Stories

Raltegravir Pharmacokinetic Targets Met in High-Risk HIV-Exposed Infants
VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding

Visit HIV i-Base's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.